SecBot SecBot
SECBOTREPLAY Home › Report › DYN

DYN · Dyne Therapeutics expanded its Hercules Capital debt facility to $400M…

Dyne Therapeutics, Inc. · 8-K filed Jun 17, 2026 at 07:35 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Jun 17, 2026 at 07:35 ET

Dyne Therapeutics expanded its Hercules Capital debt facility to $400M via a Second Amendment, borrowing an additional $50M on closing. The amendment adds two new $50M tranches and increases the final tranche by $25M, while reducing the minimum cash covenant from 60% to 40% of outstanding obligations and pushing the testing date from January 2027 to July 2027 (extendable to 2028). Outstanding debt post-borrowing is $200M, with up to $200M in additional undrawn tranches available upon milestones or lender approval. The move extends cash runway for a pre-revenue biotech with a $3.0B market cap and 85% analyst buy rating, but adds leverage and secured IP collateral, net neutral for the credit story.

  • Debt facility expanded to an aggregate of up to $400.0 million (from $325M prior structure)
  • Second Amendment added two $50M tranches and increased the final tranche by $25M
  • Borrowed $50.0 million on the Amendment Closing Date (June 16, 2026)
  • Outstanding principal after borrowing: $200.0 million

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access